Why the study?
Does targeting the ACE2-Ang 1-7/1-9 system improve outcomes or mitigate cardiac remodeling in heart failure?
Does targeting the ACE2-Ang 1-7/1-9 system improve outcomes or mitigate cardiac remodeling in heart failure?
The ACE2-Ang 1-7/1-9 system represents a promising therapeutic target for mitigating cardiac remodeling in heart failure.
May support ACE2-Ang 1-7/1-9 modulation in HF remodeling; hypothesis-generating, requires prospective outcome trials.
Cardiac remodeling (cardiac hypertrophy and fibrosis) is a hallmark of heart failure (HF). It can be induced by the abnormal elevation of several endogenous factors including angiotensin II (Ang II), which is generated from its precursor angiotensin I (Ang I) by the action of angiotensin-converting enzyme. The inhibition of this enzyme or the blockade of the Ang II receptors demonstrated a high clinical value against the progression of HF. Ang I and Ang II may also be converted into angiotensin 1-7 (Ang 1-7) and angiotensin 1-9 (Ang 1-9), respectively, by the action of angiotensin-converting enzyme 2. Both derivatives demonstrated a promising anticardiac remodeling activity especially against the detrimental effects of Ang II. This manuscript thoroughly reviews the available in vitro and in vivo data on Ang 1-7 and Ang 1-9 in the context of the treatment of HF and discusses the associated molecular mechanisms and the trials to clinically utilize Ang 1-7 mimetics for the treatment of that disease.
No takes yet. Share an insight, caveat, or question.
Naim Kittana (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: